Heart failure is a serious disease since it is often irreversible. It is estimated that more than 6.5 million people suffer from heart failure in Europe. It is the leading cause of hospitalization for patients over the age of 65. The incidence is increasing at an alarming rate because of an aging population and the burden of cardiovascular risk factors (diabetes, obesity and high blood pressure). Early interventions targeting key mechanisms, including myocardial interstitial fibrosis, could slow down progression to heart failure.
Fibro-targets ambition to identify biomarkers to predict, monitor and describe the response to myocardial interstitial fibrosis treatments in order to help resolve one of the 21st century's major health problems that affects elderly people in particular.
Last 4 years FIBRO-TARGETS has been successful in identifying novel fibrosis therapeutic targets. Together with industrial partners, FIBRO-TARGETS developed small peptides and molecules for their therapeutic inhibition. Those findings will be the beginning of further preclinical and clinical research. During a two-days interactive workshop (April 3-4, 2017), top experts in the field will discuss the latest research on therapeutic fibrosis targets. We expect not only to share vision, but also to create a momentum for future collaborations between the scientific, academic and industrial partners.
Our new paper outlining the major hypothesis and area of reasearch of our consortium has just been published on the European Journal of Heart Failure.
To read the paper click here !
FIBROTARGETS is a research program. The content of this website is not intended to give medical diagnosis, treatment or medical advice.